• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[uPAR:uPA:PAI-1:LRP]复合物在人成肌细胞运动中的作用。

Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.

作者信息

Chazaud B, Bonavaud S, Plonquet A, Pouchelet M, Gherardi R K, Barlovatz-Meimon G

机构信息

GERMEN, Faculté de Médecine, Université Paris XII Val-de-Marne, 8 Rue du Général Sarrail, Créteil Cedex, 94010, France.

出版信息

Exp Cell Res. 2000 Aug 1;258(2):237-44. doi: 10.1006/excr.2000.4934.

DOI:10.1006/excr.2000.4934
PMID:10896774
Abstract

The urokinase-type plasminogen activator system is a proteolytic system involved in tissue remodeling and cell migration. At the cell surface, receptor (uPAR)-bound urokinase (uPA) binds its inhibitor PAI-1, localized in the matrix, and the complex is internalized by endocytic receptors, such as the low-density lipoprotein receptor-related protein (LRP). We previously proposed a nonproteolytic role for the uPA system in human myogenic cell differentiation in vitro, i.e., cell fusion, and showed that myogenic cells can use PAI-1 as an adhesion matrix molecule. The aim of this study was to define the role of the uPA system in myogenic cell migration that is necessary for fusion. Using a two-dimensional motility assay and microcinematography, we showed that any interference with the [uPAR:uPA:PAI-1] complex formation, and interference with LRP binding to this complex, markedly decreased myogenic cell motility. This phenomenon was reversible and independent of plasmin activity. Inhibition of cell motility was associated with suppression of both filopodia and membrane ruffling activity. [uPAR:uPA:PAI-1:LRP] complex formation involves high-affinity molecular interactions and results in quick internalization of the complex. It is likely that this complex supports the membrane ruffling activity involved in the guidance of the migrating cell toward appropriate sites for attachment.

摘要

尿激酶型纤溶酶原激活物系统是一个参与组织重塑和细胞迁移的蛋白水解系统。在细胞表面,与受体(uPAR)结合的尿激酶(uPA)与其定位于基质中的抑制剂PAI-1结合,该复合物通过内吞受体(如低密度脂蛋白受体相关蛋白(LRP))内化。我们之前提出uPA系统在体外人成肌细胞分化(即细胞融合)中具有非蛋白水解作用,并表明成肌细胞可将PAI-1用作黏附基质分子。本研究的目的是确定uPA系统在融合所必需的成肌细胞迁移中的作用。使用二维运动分析和显微电影摄影术,我们发现任何对[uPAR:uPA:PAI-1]复合物形成的干扰以及对LRP与该复合物结合的干扰,都会显著降低成肌细胞的运动性。这种现象是可逆的,且与纤溶酶活性无关。细胞运动性的抑制与丝状伪足和膜皱褶活性的抑制相关。[uPAR:uPA:PAI-1:LRP]复合物的形成涉及高亲和力分子相互作用,并导致该复合物快速内化。这种复合物很可能支持膜皱褶活性,该活性参与引导迁移细胞至合适的附着位点。

相似文献

1
Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.[uPAR:uPA:PAI-1:LRP]复合物在人成肌细胞运动中的作用。
Exp Cell Res. 2000 Aug 1;258(2):237-44. doi: 10.1006/excr.2000.4934.
2
Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.尿激酶受体缺陷型肾成纤维细胞的促有丝分裂信号传导:一种替代性尿激酶受体和低密度脂蛋白受体相关蛋白的作用
J Am Soc Nephrol. 2004 Aug;15(8):2090-102. doi: 10.1097/01.ASN.0000135057.41526.2C.
3
Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.纤溶酶原激活物抑制剂-1对侵袭性乳腺癌细胞群体的促迁移作用。
Am J Pathol. 2002 Jan;160(1):237-46. doi: 10.1016/S0002-9440(10)64367-2.
4
Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.尿激酶型纤溶酶原激活物受体参与胰岛素样生长因子诱导的横纹肌肉瘤细胞体外迁移。
J Cell Physiol. 2003 Oct;197(1):131-8. doi: 10.1002/jcp.10352.
5
Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.参与尿激酶-1型抑制剂复合物和尿激酶原与内吞性α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白结合的区域。尿激酶受体保护尿激酶原不与内吞性受体结合的证据。
J Biol Chem. 1994 Oct 14;269(41):25668-76.
6
Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.尿激酶三方复合物(uPAR/uPA/PAI-1)在成肌细胞融合中具有非常规作用的证据。
J Cell Sci. 1997 May;110 ( Pt 9):1083-9. doi: 10.1242/jcs.110.9.1083.
7
Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.尿激酶/尿激酶受体系统:尿激酶-丝氨酸蛋白酶抑制剂复合物的内化/降解:机制与调控
Biol Chem Hoppe Seyler. 1995 Mar;376(3):143-55.
8
EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.表皮生长因子刺激的卵巢癌细胞迁移与尿激酶型纤溶酶原激活物受体的内化减少、表面表达增加和脱落增加有关。
Gynecol Oncol. 2006 Apr;101(1):28-39. doi: 10.1016/j.ygyno.2005.09.038. Epub 2005 Nov 2.
9
Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.通过定点诱变确定尿激酶型纤溶酶原激活剂-纤溶酶原激活剂抑制剂-1复合物与低密度脂蛋白受体家族内吞作用受体的结合区域。
FEBS J. 2006 Nov;273(22):5143-59. doi: 10.1111/j.1742-4658.2006.05511.x. Epub 2006 Oct 17.
10
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.尿激酶型纤溶酶原激活剂及其受体和1型抑制剂在子宫内膜癌中的临床相关性
Gynecol Oncol. 2001 Jan;80(1):48-55. doi: 10.1006/gyno.2000.6015.

引用本文的文献

1
Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR).人诱导多能干细胞来源的间充质干细胞通过分泌尿激酶型纤溶酶原激活物受体 (uPAR) 改善成肌细胞的植入。
Stem Cell Res Ther. 2021 Oct 9;12(1):532. doi: 10.1186/s13287-021-02594-1.
2
Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9.低密度脂蛋白受体相关蛋白1通过诱导基质金属蛋白酶2和9的表达促进癌细胞迁移和侵袭。
Cancer Res. 2009 Feb 1;69(3):879-86. doi: 10.1158/0008-5472.CAN-08-3379. Epub 2009 Jan 27.
3
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
纤溶酶原激活物抑制剂-1与乳腺癌细胞迁移中SNAI1的功能阻断
Breast Cancer Res. 2008;10(6):R100. doi: 10.1186/bcr2203. Epub 2008 Dec 3.
4
Fluorescence correlation spectroscopy and photon counting histogram on membrane proteins: functional dynamics of the glycosylphosphatidylinositol-anchored urokinase plasminogen activator receptor.膜蛋白的荧光相关光谱和光子计数直方图:糖基磷脂酰肌醇锚定的尿激酶型纤溶酶原激活剂受体的功能动力学
J Biomed Opt. 2008 May-Jun;13(3):031215. doi: 10.1117/1.2940570.
5
Urokinase and its receptors in chronic kidney disease.慢性肾脏病中的尿激酶及其受体
Front Biosci. 2008 May 1;13:5462-78. doi: 10.2741/3093.
6
The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization.HKa在内皮细胞管腔形成中的抑制作用是通过破坏uPA-uPAR复合物并抑制其信号传导和内化来介导的。
Am J Physiol Cell Physiol. 2008 Jul;295(1):C257-67. doi: 10.1152/ajpcell.00569.2007. Epub 2008 May 21.
7
LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities.尽管细胞周围蛋白水解活性增加,但LRP-1沉默仍可阻止恶性细胞侵袭。
Mol Cell Biol. 2008 May;28(9):2980-95. doi: 10.1128/MCB.02238-07. Epub 2008 Mar 3.
8
uPA deficiency exacerbates muscular dystrophy in MDX mice.尿激酶型纤溶酶原激活剂缺乏会加重MDX小鼠的肌肉萎缩。
J Cell Biol. 2007 Sep 10;178(6):1039-51. doi: 10.1083/jcb.200705127. Epub 2007 Sep 4.
9
Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing.纤溶酶原激活物抑制剂1在作为可溶性因子以及作为肺泡上皮细胞伤口愈合的基质细胞调节因子方面的双重作用。
Am J Pathol. 2006 Nov;169(5):1624-32. doi: 10.2353/ajpath.2006.051053.
10
Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth.卫星细胞吸引单核细胞,并利用巨噬细胞作为支持来逃避凋亡并增强肌肉生长。
J Cell Biol. 2003 Dec 8;163(5):1133-43. doi: 10.1083/jcb.200212046.